Institute of Metabolic Diseases, Guang' Anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, 100053, China; Graduate College, Beijing University of Chinese Medicine, Beijing, 100029, China.
College of Traditional Chinese Medicine, Changchun University of Chinese Medicine, Changchun, 130117, China.
J Ethnopharmacol. 2024 Apr 6;323:117663. doi: 10.1016/j.jep.2023.117663. Epub 2024 Jan 3.
Conventional treatments for Hashimoto's thyroiditis (HT) are limited. Herbal medicines (HM) are considered a potential intervention for the treatment of HT.
This study aimed to investigate the efficacy and safety of HM for HT.
A Bayesian network meta-analysis was conducted for patients with HT in randomized controlled trials identified in PubMed, Cochrane Library, Web of Science, EMBASE, Chinese Clinical Trial Registry (Chi CTR), China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (the VIP), China Chinese Biomedical Database (CBM), and Wanfang Database were searched from their inception to Oct 1, 2022. Outcomes included the primary outcome (TPOAb), secondary outcomes (TSH, TGAb, FT3, FT4, and traditional Chinese medicine symptom scores), and adverse events. This study was registered in PROSPERO (CRD42022363640).
Sixteen trials were reviewed and 16 HM formulae were compared. Compared with non-drug therapy (NDT), all therapies, except for Tiaoqi-Qingjie Therapy, reduced the primary outcome of TPOAb with different levels of effectiveness, ranging from 0.01 (95%CI 0.00, 0.02) to 0.92 (95%CI 0.56, 1.53). Ranking probability analysis indicated that Yiqi Huayu Recipe, Liqi Xiaoying decoction, and Shugan Sanjie therapy reduced thyroid antibody levels the most, including TPOAb (100.0%, 90.9%, and 90.3%, respectively) and TGAb (98.3%, 94.4%, and 87.3%, respectively). All HMs displayed a significant effect on the TCM Symptom score and possibly benefitted the treatment of HT, ranging from 6.62 (95% CI 2.06, 21.24) to 94.50 (95% CI 15.97, 559.14). No serious adverse events were reported.
Herbal medicines may be effective in the treatment of HT, especially in reducing thyroid antibody levels and improving clinical symptoms without affecting thyroid function. However, these results should be considered preliminary and further verified using high-quality evidence.
桥本甲状腺炎(HT)的常规治疗方法有限。草药(HM)被认为是治疗 HT 的一种潜在干预方法。
本研究旨在探讨 HM 治疗 HT 的疗效和安全性。
对在 PubMed、Cochrane 图书馆、Web of Science、EMBASE、中国临床试验注册中心(Chi CTR)、中国国家知识基础设施(CNKI)、中国科技期刊数据库(the VIP)、中国生物医学文献数据库(CBM)和万方数据库中检索到的 HT 患者随机对照试验进行贝叶斯网络荟萃分析。这些研究的时间范围为从成立到 2022 年 10 月 1 日。结局包括主要结局(TPOAb)、次要结局(TSH、TGAb、FT3、FT4 和中医症状评分)和不良反应。本研究已在 PROSPERO(CRD42022363640)注册。
共评价了 16 项试验,比较了 16 种 HM 配方。与非药物治疗(NDT)相比,除调气清热疗法外,所有疗法均能不同程度地降低 TPOAb 的主要结局,有效率范围为 0.01(95%CI 0.00,0.02)至 0.92(95%CI 0.56,1.53)。排序概率分析表明,益气化瘀方、理气消痈汤和疏肝散结疗法降低甲状腺抗体水平的效果最为显著,包括 TPOAb(100.0%、90.9%和 90.3%)和 TGAb(98.3%、94.4%和 87.3%)。所有 HM 对中医症状评分均有显著影响,可能有益于 HT 的治疗,疗效范围为 6.62(95%CI 2.06,21.24)至 94.50(95%CI 15.97,559.14)。未报告严重不良事件。
草药可能对 HT 有效,特别是在降低甲状腺抗体水平和改善临床症状方面,而不影响甲状腺功能。然而,这些结果应被认为是初步的,需要使用高质量的证据进一步验证。